ForPatients
by Roche

Healthy Volunteers

A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT06809608 2024-517360-37-00 BP45670

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a single-center, non-randomized, open-label, cross-over study in healthy male and female participants. Part 1 of the study has a 2-period (a single fixed sequence) design and will investigate the impact of itraconazole on the pharmacokinetics (PK) of RO7795081 in healthy participants. A maximum of up to 25 participants will be enrolled in Part 1 and sequentially undergo Period 1 (RO7795081 alone) followed by Period 2 (RO7795081 with itraconazole). Part 2 of the study has an adaptive design with up to 4 periods (a single fixed sequence) and will investigate the impact of gemfibrozil and cyclosporine on the PK of RO7795081 in healthy participants. A maximum of up to 25 participants will be enrolled in Part 2 and sequentially undergo Period 1 (RO7795081 alone) followed by Period 2 (RO7795081 with gemfibrozil), Period 3 (RO7795081 with cyclosporine 200 mg), and finally Period 4 (RO7795081 with cyclosporine #600 mg).

Hoffmann-La Roche Sponsor	**Phase 1** Phase

NCT06809608 2024-517360-37-00 BP45670
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years & <= 65 Years	Accepts Healthy Volunteers

© 2022 F. Hoffmann-La Roche Ltd